The prevalent adverse effects of coronavirus vaccines across the world are beginning to be of concern to vaccine producers. The producers are beginning to develop loss of confidence on the vaccines being rolled out for the containment of coronavirus. They are, therefore, contemplating yearly COVID vaccination , in place of the quarterly vaccination.
The ineffectiveness of the vaccines to protect the vaccinated in the first shot, led to the enforcement of the second dose. Again, the failure of the second shot to prevent the spread of coronavirus, according to the promoters of the pandemic, led to the enforcement of the third shot, celebrated as a booster jab. Now, the third vaccine shot is failing as the vaccinated are now prone and more vulnerable to COVID infection than the unvaccinated. The producers of coronavirus vaccines are now contemplating yearly covid vaccination rather than periodic vaccination. The loss of confidence on the efficacy of the coronavirus vaccines is increasing, leading to frustration of the producers of vaccines, even though their vaccine business is profitable to them.
A bigger problem for the vaccine producers is the emergence of new variants of coronavirus after the initial production of COVID vaccines. They have not been able to develop the technology for the production of vaccines for the new variants, like Omicron. Yet, governments are compelling citizens to take vaccines that are not meant for Omicron, which is claimed to be spreading widely.
In most countries, including Australia, citizens now prefer to be infested by coronavirus than accept the vaccines. The vaccines have become more dangerous and deadly than the virus the vaccines are meant to prevent.
The Chief Executive of Pfizer, Albert Bourla, in Israel recommended yearly coronavirus vaccination and stoppage of periodic booster COVID vaccine jabs. Bourla had stated that “an annual COVID vaccine jab would be preferable to more frequent booster shots in fighting the coronavirus pandemic.”
The Pfizer CEO objected to booster shots administered every four to five months on a regular basis. According to Bourla, “This will not be a good scenario. What I’m hoping that we will have a vaccine that you will have to do once a year.
“We are looking to see if we can create a vaccine that covers Omicron and doesn’t forget the other variants and that could be a solution.”
Bourla added that Pfizer may seek approval for a redesigned vaccine to fight Omicron, and embark on mass production as soon as March.